81. FINNISH GENE THERAPY SOCIETY - MAIN PAGE Fosters the exchange of ideas between research groups and individual scientists, organizes scientific meetings and training courses and informs general public about basic aspects and recent developments in gene therapy. http://www.uku.fi/english/organizations/fgts/index.htm

MESSAGE FROM THE PRESIDENT Dear Friends, Gene therapy has matured as an exciting new field of research which will have a significant impact on biology and medicine during the next decade. Both pathogenesis of various diseases and basic biological pathways can be studied by gene transfer techniques. Thus, gene transfer will provide a versatile tool for researchers to solve emerging biological questions. However, it is also evident that systematic basic research is needed to improve gene transfer vectors and delivery methods before the full potential of gene transfer techniques can be realized. Finnish scientists have been active in the field of gene therapy for several years. Since the number of researchers engaged in gene transfer and gene therapy studies has steadily increased, it was felt that it is time to establish Finnish Gene Therapy Society. The major aims of the Society are to foster the exchange of ideas between research groups and individual scientists, to organize scientific meetings and training courses and to inform general public about basic aspects and recent developments of gene therapy. Finnish Gene Therapy Society will also establish a Fund for travel grants for promising young scientists. We plan to maintain an updated www home page in order to improve exchange of ideas and information in the field of gene therapy. I am looking forward to working with you to create a very active and stimulating Society. I also welcome all comments and suggestions regarding future activities of the Society.

82. Biotechnology Resources Lists high tech companies in such fields as bioinformatics, gene therapy and immunology. http://www.biotechnologycompany.org/

Home About Us News Resources ... Contact Us Resources Bioinformatics Cloning Contract Research Ethics ... Proteomics

83. The Journal Of Gene Medicine Articles on gene therapy including design and production of vectors, research into the mechanisms underlying gene transfer, preclinical studies including animal models, developmental aspects and clinical trials. http://www.interscience.wiley.com/jpages/1099-498X/

Official Journal : European Society of Gene Therapy (ESGT) Japan Society of Gene Therapy (JSGT) Australasian Gene Therapy Society (AGTS) Journal of Gene Medicine Impact Factor Increases from 3.103 to 4.835*! With the new ISI Journal Citation Report being released Wiley is very pleased to announce that the Journal of Gene Medicine ’s impact factor has increased from 3.103 to 4.835* placing it in the top 20 of the ISI genetics journal listing. *ISI Journal Citation Report 2001 Online ISSN: 1521-2254 Print ISSN: 1099-498X Contact Us

84. Txt001jfo: Gene Therapy: Potential Applications In Clinical Transplantation gene therapy potential applications in clinical transplantation.Jeremy W. Fry and Kathryn J. Wood. Gene What is gene therapy? A http://www-ermm.cbcu.cam.ac.uk/99000691h.htm

Expert Reviews in Molecular Medicine: http://www-ermm.cbcu.cam.ac.uk Accession information: (99)00069-1h.htm (shortcode: txt001jfo); 8 June 1999 Request PDF version Discussion Group How to cite this article Gene therapy: potential applications in clinical transplantation Jeremy W. Fry and Kathryn J. Wood Author contact details In this review, we have discussed the basic principles of gene therapy and described the various vectors that are currently used both in research and in the clinic to deliver introduced genes (transgenes) to target tissues. The implications of gene transfer strategies to transplantation and potential future applications have also been reviewed. Allograft rejection and immunological tolerance For the foreseeable future, patients will continue to be transplanted with allogeneic organs which, by definition, are not identical at the major histocompatibility complex (MHC) locus. Without any other treatment, such as the administration of immunosuppressive drugs, the immune response generated by the recipient, which is mainly T-cell mediated, will reject such a graft (Fig. 1; What is gene therapy?

85. NEUROLAB Specializing in preclinical pharmacology testing of drugs targeting central nervous system diseases. Also provides CNS gene therapy research including transgene construction, characterization of transgene expression and in-vivo testing. http://neurolab.fr

NEUROLAB Biological Research Laboratory Your Research Partner In-Vivo Platform Functional Proteomics Platform Multiple Biomarkers Analysis NEW..... OUR ONGOING PROTEOMICS PLATFORM ...OUR NEW WEBSITE IS COMING SOON.Click Here l News l Company Profile l Services l Contact us l Job Opportunity l Last update: February 09th 2002 Best view on PC/Explorer

86. Washingtonpost.com Gene Research Jesse Gelsinger• gene therapy Death Jesse Gelsinger, 18, died in September1999 after a failed experimental therapy administered by the University of http://www.washingtonpost.com/wp-dyn/health/specials/genetherapy/

Knowing more about our audience will help us continue to improve our web site and provide ads that are relevant to our audience. It's fast and it's FREE. Please fill out the form below to proceed. Gender: Male Female Year of Birth: Zip: (U.S. Only) (e.g. 1965) (e.g. 20171) Country: United States United States Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil British Virgin Islands Brunei Bulgaria Burkina Faso Burma Burundi Cambodia Cameroon Canada Cayman Islands Cape Verde Central African Republic Chad Chile China Colombia Comoros Congo (Zaire) Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Fiji Finland France French Guiana French Polynesia Gabon The Gambia Gaza Strip and West Bank Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti The Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Ivory Coast Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Federated States of Micronesia Moldova Monaco Mongolia Montserrat Morocco Mozambique

87. GT Index Page Publishes research about the identification of gene structure, disease processes and the development of clinical methods to treat disease. Includes instructions for authors and related journals. http://www.naturesj.com/gt/

nature.com about npg nature science update naturejobs ... help SEARCH my account e-alerts subscribe register ... Journal home For readers Content Online sample issue E-alerts Indexed in ... Society publishing NPG Subject areas Access material from all our publications in your subject area: Biotechnology Cancer Chemistry Clinical Medicine ... Physics ISSN 0969-7128 2003 Volume 10 Publishes 24 issues a year ISI 2001 Impact Factor 5.893 Rank 13/113 Genetics and Heredity, 42/308 Biochemistry and Molecular Biology View tables of contents At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies and the development of clinical methods to treat disease. online submission..... Now available with Gene Therapy Recent papers in the Progress and Prospects Review Series Limb and heart ischemia Alpha-1 antitrypsin Nonviral vectors ... Post-intervention vessel remodeling Audience Clinicians and researchers with an interest in genetic disease and the use of genetic techniques in disease control.

88. Welcome To Gene Therapy Press Our website of the Journal of gene therapy Molecular Biology allows you to browseand download fulltext articles, published in Volume 1, 3 and 4 - 6. http://www.gtmb.org/

Our website of the allows you to browse and download full-text articles, published in Volume 1, 3 and 4 - 6 Full-text articles of Volume 1, 3 and 4 are already available! Volume 5 and 6 will follow as we are in the process of updating of this site Make sure you have the latest version of Acrobat Reader installed on your computer

89. Laboratory Of Transplantation Immunology-UNMC Confronting research in human immunology, gene therapy, nonviral vector peptide vaccines, cell adhesion and mucosal immunology for therapeutic application at the University of Nebraska Medical Center, Omaha, NE. http://www.unmc.edu/Pathology/transimm

James E. Talmadge, Ph.D., director How to reach us University of Nebraska Medical Center Laboratory of Transplantation Immunology Dept. of Pathology and Microbiology 987660 Nebraska Medical Center Omaha, NE 68198-7660 USA Phone: +1 402 559 5639 Fax: +1 402 559 4990 email: jtalmadg@unmc.edu Photo by George Pallas, July 2000 The Laboratory of Transplantation Immunology is an area brimming with activity. Under the direction of James Talmadge, Ph.D., the faculty, members and fellows in the laboratory, Drs. Lee Mosley, Vladimir Pisarev, Simon Robinson and Rakesh Singh are involved in research emphasizing molecular immunology, human immunology, vaccines, metastasis, gene therapy, and cytokine biology. At present, the Laboratory of Transplantation Immunology is involved in studying the mechanism of immunologic reconstitution following stem cell transplantation. This includes studies on the molecular reconstitution of cytokines, cellular phenotypes and function and the role of death proteins in peripheral tolerance following transplantation. The Laboratory also focuses on the effects of product manipulation and the role of cytokines, cell adhesion molecules, chemokines, and lymphokines in hematopoietic stem cell mobilization.

90. St. Elizabeth's Medical Center: Research Conducts gene transfer research and clinical trials for those who suffer from coronary artery disease and peripheral vascular disease under the direction of Dr. Jeffrey Isner and his colleagues. http://www.semc.org/departments/gene_transfer.asp

Anesthesiology Cardiovascular Rehabilitation Emergency Care Gene Transfer ... Potential Risks and Benefits of Gene Transfer St. Elizabeth's Medical Center continues to be on the cutting edge of gene transfer research. We are currently conducting clinical trials for those who suffer from peripheral artery disease. We anticipate resuming the trials for those who suffer from coronary artery disease in the very near future. Gene transfer is an investigational therapy not approved for use in the general public. Not everyone is eligible to participate in the trials. Peripheral Artery Disease Gene Transfer Information Primary Objectives of Research Study 1. To evaluate the safety of intramuscular administration of pVGI.1 (VEGF2) or AD2/HIF-1Alpha/VP16 versus a placebo (salt water injection) in adult patients with moderate or high risk critical limb ischemia (significantly decreased blood flow) by assessing the frequency, duration, and severity of adverse events. 2. To assess, in adult patients with moderate risk ischemia, the effect on resting leg pain (as assessed by frequency of rest pain, pain medication use history, sleep history, and intensity of rest pain) of single, defined doses of pVGI.1(VEGF2) or AD2/HIF-1Alpha/VP16 given by direct intramuscular injection into the affected leg when compared to placebo.

91. UVA/OEHS - Gene Therapy Safety Home Page gene therapy Regulatory Requirements Guidelines to assist the clinicalinvestigator in opening a gene therapy study on the GCRC. http://keats.admin.virginia.edu/gene/home.html

Regulatory Requirements Safety Practices Serious Adverse Event Reporting Registration Document Biosafety Manual Gene Therapy HOME PAGE UVA Policy on Gene Transfer Research Trials (PDF) Gene Therapy Regulatory Requirements - Guidelines to assist the clinical investigator in opening a gene therapy study on the GCRC. The GCRC will confirm that a protocol is approved by all of the necessary review committees before the first patient is enrolled. Investigators may choose to submit a proposal to the NGVL for clinical grade vector for use in human trials. Gene Therapy Safety Practices - In addition to the standard policies, procedures, and protocols established by the Director of the GCRC, appropriate special policies and procedures must be developed as needed for approval by the Human Investigation Committee (HIC) and the Institutional Biosafety Committee (IBC). Gene Therapy Adverse Event Reporting - A recent (November 22, 1999) Notice of Proposed Actions under the "NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)" introduces a requirement for the immediate notification of any Serious Adverse Event to the local Institutional Review Board (IRB), the Institutional Biosafety Committee (IBC), Office for Protection from Research Risks (OPRR) (if applicable), NIH/Office of Biotechnology Activities (OBA), and the Food and Drug Administration (FDA).

92. UVA/OEHS - Gene Therapy Safety Practices gene therapy Safety Practices. Adobe Acrobat PDF gene therapy Safety Practices.GENERAL gene therapy SAFETY PRACTICES FOR THE GCRC. Standard Practices. http://keats.admin.virginia.edu/gene/gene_therapy_safety_practices.html

Regulatory Requirements Safety Practices Serious Adverse Event Reporting Registration Document Biosafety Manual Gene Therapy HOME PAGE Gene Therapy Safety Practices In addition to the standard policies, procedures, and protocols established by the Director of the GCRC, appropriate special policies and procedures must be developed as needed for approval by the Human Investigation Committee (HIC) and the Institutional Biosafety Committee (IBC). Please download in the format of your choice or see below. MS Word 97 Gene Therapy Safety Practices Adobe Acrobat PDF Gene Therapy Safety Practices GENERAL GENE THERAPY SAFETY PRACTICES FOR THE GCRC Standard Practices In addition to the standard policies, procedures, and protocols established by the Director of the GCRC, appropriate special policies and procedures must be developed as needed for approval by the Human Investigation Committee (HIC) and the Institutional Biosafety Committee (IBC). The document to be submitted for review by the IBC is entitled Gene Therapy Registration Document Access to the treatment room is limited to the fewest number of individuals possible. Personnel who must enter the room for program or service purposes when work is in progress are advised of the potential hazard. An appropriate medical surveillance program is in place. All personnel receive appropriate immunizations or tests for the agents handled or potentially present. When appropriate, a serum surveillance system is implemented.

93. USC Center For Vascular Disease Latest updates on gene therapy in treatment of vascular disease. http://www.surgery.usc.edu/divisions/vas/research.html

USC Vascular surgery specialists focus not only on survival, but on continued quality of life. The USC Vascular surgery program is built on excellence in patient treatment combined with advances in basic research. Advanced gene transfer techniques are being developed. Coordinating these efforts is Hong Yu, PhD . Hong Yu, PhD, Assistant Professor of Research, joined the USC faculty in 1996 after being trained in the USC Gene Therapy Laboratories headed by Dr. W. French Anderson, a pioneer of human gene therapy. The research team is studying the genetic engineering of vascular bypass grafts. The project purpose is to improve the patency rate of prosthetic and autogenous bypass grafts. Through gene transfer, the cells on bypass grafts are being made to overexpress a thrombolytic enzyme that will prevent clot formation. The long term goal of the project is to use the implanted conduits as a drug delivery system to deliver a variety of therapeutic proteins/drugs into the circulation. The research project is supported by American Heart Association, Pacific Vascular Foundation, May R. Wright Foundation, James Zumberge Fund, Bank of America-Giannini Foundation, Charles E. Culpeper Foundation.

94. Gene Therapy gene therapy. Many human diseases are caused by defective genes. A fewcommon examples Disease, Genetic defect. gene therapy requirements. http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/G/GeneTherapy.html

Index to this page Severe Combined Immunodeficiency (SCID) Treatment Options: Gene Therapy: requirements Packaging Cells ... Gene Therapy for X-linked SCID Gene Therapy Many human diseases are caused by defective genes. A few common examples: Disease Genetic defect hemophilia A absence of clotting factor VIII cystic fibrosis defective chloride channel protein muscular dystrophy defective muscle protein (dystrophin) sickle-cell disease defective beta globin hemophilia B absence of clotting factor IX severe combined immunodeficiency (SCID) any one of several genes fail to make a protein essential for T and B cell function All of these diseases are caused by a defect at a single gene locus . (The inheritance is recessive so both the maternal and paternal copies of the gene must be defective.) Is there any hope of introducing functioning genes into these patients to correct their disorder? Probably. Other diseases, also have a genetic basis, but it appears that several genes must act in concert to produce the disease phenotype . The prospects of gene therapy in these cases seems far more remote. Case study: severe combined immunodeficiency (SCID) SCID is a disease in which the patient has neither cell-mediated immune responses nor is able to make antibodies It is a disease of young children because, until recently, the absence of an immune system left them prey to infections that ultimately killed them.

95. UNC Gene Therapy Center Working to translate gene therapy research from the laboratory bench into Phase I clinical trials for the treatment of hematologic and endocrine diseases. The center has a GMP facility for clinical grade gene vector production. http://www.med.unc.edu/genether/

This page utilizes frames.

96. Gene Therapy And Regulation gene therapy and Regulation. Editorin-Chief Roger Bertolotti CNRS,Molecular Genetics Department of Hepato-Gastroenterology Faculty http://www.vsppub.com/journals/jn-GenTheReg.html

You can now add your name to our electronic mailing list Online edition Table of Contents Editorial Board ... Contacts Gene Therapy and Regulation Editor-in-Chief: Roger Bertolotti CNRS, Molecular Genetics Department of Hepato-Gastroenterology Faculty of Medicine, University of Nice - Sophia Antipolis Avenue de Valombrose F-06107 Nice, France Tel: +33 4 9381 7381 Fax: +33 4 9331 7253 Roger.Bertolotti@unice.fr The aim of Gene Therapy and Regulation is to meet the demand for an international interdisciplinary journal integrating the publication of all aspects of research on gene therapy and ancillary approaches, i.e. molecular cloning, sequencing and gene regulation. The journal fulfils this aim by publishing regular research papers, short communications and - by invitation - occasional review papers. Gene Therapy and Regulation welcomes submissions of papers which report original research data on molecular cloning, gene regulation, RNA/DNA transfer into mammalian cells and subsequent gene expression, alteration or inactivation. Papers from both basic research (molecular cloning/sequencing, gene regulation, design and development of vectors, delivery systems, biological and therapeutic effects, cellular and animal models) and from clinical trials and investigations will be considered. Call for NIH grant applications ISSN 1388-9532 E-ISSN 1568-5586 Indexed/Abstracted in: Chemical Abstracts/EMBASE: Excerpta Medica Subscription data 2003: Volume in issues Institutional rate: EUR 212 US$ 245

97. ML Research Discovers And Develops Tumour Specific, Targeted Cancer Therapies Th Researchers and developers of tools that address key aspects of gene therapy. Includes product portfolio and details on technologies as well as contact information and location. http://www.mlresearch.co.uk/

Company Facilities Location Contact Careers Product Portfolio Gene Directed Chemotherapy Genetic Vaccination Technologies Expression Technologies Non-viral Gene Delivery Home The Research Division of ML Laboratories plc discovers and develops tumour-specific, targeted cancer therapies that exploit ML's proprietary technologies. The company intends to maximise its value by developing products that have different modes of action and currently has two product development programmes. 1. Gene Directed Chemotherapy with product in Phase I/II trials 2. Gene Vaccination with product expected to enter Phase I trials in 2002 Business Strategy The company intends to commercialise its clinical development candidates in partnership with major pharmaceutical companies or biotechnology companies. ML Research Division also develops tools that address the four key aspects of gene therapy: expression, delivery, manufacture and safety. Its technologies reach beyond gene therapy to include protein production/manufacture, vaccine development, and functional genomics and drug discovery in general. Out-licensing Opportunities Although its technologies are used in-house for manufacturing or development of products for cancer therapy, they are also available for licensing to pharmaceutical and biotechnology companies.

98. PEGT: Introdcution To The Program Printable Version. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE. PROGRAMSOF EXCELLENCE IN gene therapy FOR HEART, LUNG, AND BLOOD DISEASES. http://www.med.cornell.edu/pegt/

Screen Reader/Printer Friendly Version NATIONAL HEART, LUNG, AND BLOOD INSTITUTE PROGRAMS OF EXCELLENCE IN GENE THERAPY FOR HEART, LUNG, AND BLOOD DISEASES Welcome to the NHLBI Programs of Excellence in Gene Therapy for Heart, Lung, and Blood Diseases Home Page The purpose of the PEGT Website is to provide information about the PEGTs' basic and clinical projects and their available resources (vector production cores, cell morphology core, hematopoietic stem cell processing core and primate stem cell transplantation core). The website will also include electronic versions of the applications that are necessary for requesting any available PEGT services or training. Applications may be filed electronically so as to expedite the process. The administrative organization of the PEGTs is a collaborative effort between the NHLBI staff and the supported investigators. To facilitate this, several committees have been established such as an Inter-Program Steering Committee, an External Scientific Panel and Internal Advisory Committees. A Data and Safety Monitoring Board has been appointed by the Director, NHLBI to provide overall monitoring of interim data and safety issues. In addition, a Data and Coordinating Center has been established to coordinate a range of functions that is common to NHLBI and all the PEGTs.

99. THE JANAN SOCIETY OF GENE THERAPY Facilitates interdisciplinary gene therapy research between investigators performing basic and applied research and clinical trials through academic conferences, international symposia and publications. http://bizweb.justnet.ne.jp/~jsgt/

THE 9TH ANNUAL MEETING Last Update : March 5, 2003 New Information from Journal of Gene Medicine Comment on Emergency Report "Reports of second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency(X-SCID)" JSGT-Comment(Japanese) Up-To-Date(Jap) ! Click! ESGT-Press release JSGT-Web Links Click ! General Information President : Shigetaka Asano The Institule of Medical Science, The University of Tokyo Date: The Annual Meeting : July 18 (Fri.) - 20(Sun.), 2003 International Symposium July 18-20, 2003 Venue: Yayoi Auditorium Address: 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8654, Japan Tel: (+81)-3-3812-2111 ... jsgt@js9.so-net.ne.jp JSGT: Our Office has moved ! Effective on April 1, 2001, please contact Japan Society of Gene Therapy at: JSGT: Public Health Research Foundation, ST-Bldg.,7th Floor, 4, 7-4, Shirokanedai, Minato-ku, Tokyo, 108-0071, Japan. Tel: 81-3-5447-5264 Fax: 81-3-5791-1762, E-mail:jsgt@js9.so-net.ne.jp Any question or recommand please contact us! @ HERE

100. PEGT: Centers - University Of Pittsburgh/Cardiovascular Gene Therapy Printable Version. Cardiovascular gene therapy Cardiovascular GeneTherapy Overview Program Director - Joseph Glorioso, PhD. The http://www.med.cornell.edu/pegt/pegtCenters_UofP.html

Screen Reader/Printer Friendly Version Cardiovascular Gene Therapy Cardiovascular Gene Therapy Overview - Program Director - Joseph Glorioso, PhD Project 1 - Gene Transfer During LVAD Support. A. Feldman Project 2 - ... R. Simmons - National Vector Production Cores: Cornell University/University of Pittsburgh Clinical Grade Vector Production Cores University of Pittsburgh Pre-Clinical Grade Vector Production Core Users of Assistive Technologies: Click here to report any problems with the usability of the PEGT site. Web Master ... NHLBI Home

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 169    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | Next 20